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Pyocin and immunity 
protein gene position 
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1Pyocinalso present2 other P. aeruginosa 
s. Immunity protein present in 40 other P. aeruginosa 
s. 
2Pyocinalso present102 other P. aeruginosa 
s. Immunity protein present in 40 other P. aeruginosa 
s. 
3Pyocinalso present2 other P. aeruginosa 
s. Immunity protein present in 17 other P. aeruginosa 
s. 
























ΔS (cal mol-1 
deg-1) 
Kd (±)a (μM) 
Average Kd 
(±)b (μM) 
SD2 300 3.0  -25.0 (2.4) 0.11 (0.01) -55 0.93 (0.09) 
0.58 (0.36) 
SD2 150 3.0 -17.4 (0.7) 0.11 (0.00) -28 0.22 (0.02) 
S2 75 3.0  -16.6 (0.6) 0.12 (0.00) -24 0.14 (0.03) 
0.38 (0.24) 
S2 150 3.0 -18.3 (0.9) 0.11 (0.00) -33 0.62 (0.04) 
S5 300 3.0 -28.5 (3.9) 0.13 (0.01) -68 1.94 (0.19) 
1.19 (0.75) 
S5 150 3.0 -17.9 (0.6) 0.14 (0.00) -31 0.44 (0.01) 
AP41 100  1.0  ND - - - - 
 AP41 150  3.0 ND - - - 
SD1 300  3.0 ND - - - - 
 SD1 300  3.0 ND - - - 
SD3 257 3.0 -23.4 (2.8) 0.10 (0.01) -51 1.84 (0.17) 
1.47 (0.37) 
SD3 150 3.0 -16.3 (0.9) 0.12 (0.00) -27 1.10 (0.04) 
S2Δ318 257 3.0 ND - - - - 
 S2Δ318 150 3.0 ND - - -
S2(209) 300 3.0 ND - - -  
- S2(209) 175 1.0 ND - - -
SD2Δ216 300 3.0 -47.0 (4.0) 0.10c -134 21.32 (0.55) 
22.31 (0.99) 
SD2Δ216 300 3.0 -67.8 (5.8) 0.10c -203 23.29 (0.59) 
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b M f  w dd x (± SEM)  1012 
 N fxd  1 f f ( Md)  1013 
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